---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-017917"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:52:53.590162+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA lifts clinical hold on DiaMedica's DM199 acute ischemic stroke trial

## Summary
- FDA removed clinical hold on IND for DM199 phase 2/3 ReMEDy2 trial in acute ischemic stroke.
- Hold removal allows DiaMedica to proceed with enrollment and dosing in the trial.
- Investor presentation summarizing the update made available on June 21, 2023.
- No financial guidance or trial timeline details disclosed in the filing.

## SEC filing metadata
- accession: 0001437749-23-017917
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923017917/0001437749-23-017917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923017917/dmtp20230620c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-017917
- JSON: https://secwatch.observer/filing/0001437749-23-017917.json
- Plain text: https://secwatch.observer/filing/0001437749-23-017917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.